Co‐expression of <scp>LAG</scp>3 and <scp>TIM</scp>3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients

Qiang Ma, Junning Liu, Guoliang Wu, Mujian Teng, Shaoxuan Wang, Meng Cui, Yuantao Li

Clinical and Experimental Pharmacology and Physiology · 2018 · 42 citations · 15 references

Abstract

Regulatory T (Treg) cells are critical suppressors of inflammation and are thought to exert mainly deleterious effects in cancers. In colorectal cancer (CRC), Foxp3<sup>+</sup> Treg accumulation in tumors was associated with poor prognosis. Hence, we examined the circulating Treg cells in CRC patients. Compared to controls, CRC patients presented mild upregulations in CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells and in the more canonical CD4<sup>+</sup> CD25<sup>+/hi</sup> Foxp3<sup>+</sup> Treg cells in peripheral blood mononuclear cells. Both of these Treg populations could be roughly divided into lymphocyte activation gene 3 negative T cell immunoglobulin and mucin-domain containing-3 negative (LAG3<sup>-</sup> TIM3<sup>-</sup> ) and LAG3<sup>+</sup> TIM3<sup>+</sup> subsets. In CRC patients, the LAG3<sup>+</sup> TIM3<sup>+</sup> subset represented approximately half of CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells and greater than 60% of CD4<sup>+</sup> CD25<sup>+/hi</sup> Foxp3<sup>+</sup> Treg cells, which was significantly more frequent than in healthy controls. Compared to the LAG3<sup>-</sup> TIM3<sup>-</sup> CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells, the LAG3<sup>+</sup> TIM3<sup>+</sup> CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells presented considerably higher transforming growth factor-β and slightly higher interleukin (IL)-10 secretion, together with higher cytotoxic T-lymphocyte associated protein 4 and Foxp3 expression levels. Notably, macrophages following incubation with LAG3<sup>-</sup> TIM3<sup>-</sup> CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells and LAG3<sup>+</sup> TIM3<sup>+</sup> CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells displayed different characteristics. Macrophages incubated with LAG3<sup>+</sup> TIM3<sup>+</sup> CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells presented lower expression of major histocompatibility complex class II, CD80, CD86, and tumor necrosis factor-α but higher expression of IL-10, than macrophages incubated with LAG3<sup>-</sup> TIM3<sup>-</sup> CD4<sup>+</sup> CD25<sup>+/hi</sup> T cells. Together, our investigations demonstrated that CRC patients presented an enrichment of circulating Treg cells, in which the LAG3<sup>+</sup> TIM3<sup>+</sup> subset exhibited more potent expression of inhibitory molecules, and furthermore, the LAG3<sup>+</sup> TIM3<sup>+</sup> Treg cells could suppress the proinflammatory activation of macrophages more potently than the LAG3<sup>-</sup> TIM3<sup>-</sup> Treg cells.

References

15